WAM
TGTX icon

Wealthspire Advisors (Maryland)’s TG Therapeutics TGTX Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-103
Closed -$1K – 1836
2015
Q4 		$1K Buy
+103
New +$1.3K ﹤0.01% 1652

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s TGTX Position: Q1 2016 in Review

Wealthspire Advisors (Maryland) sold out of TG Therapeutics (TGTX) in Q1 2016, closing a stake of 103 shares — an estimated $1K sold.

Wealthspire Advisors (Maryland) first reported a position in TGTX in Q4 2015 and held it in 1 quarter. The position peaked at $1K in Q4 2015. 81 funds tracked by Wall St. Rank hold TGTX as of Q1 2016.

  • Wealthspire Advisors (Maryland) reported no remaining TG Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 103 TG Therapeutics shares in Q1 2016, an estimated $1K.
  • Wealthspire Advisors (Maryland) first reported a position in TG Therapeutics in Q4 2015 and held it in 1 quarter.
  • Wealthspire Advisors (Maryland)'s TG Therapeutics position peaked at $1K in Q4 2015.
  • 81 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2016.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q1 2016, filed 6 May 2016.